Regulatory approval

Published by the Health Products Regulatory Authority. Approved

The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.

This is written in the approval document as:

Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Citation

Laboratoires Juvise Pharmaceuticals. Arimidex 1mg Film-coated Tablets (Anastrozole) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf. Revised June 2021. Accessed May 25, 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HPRA (1)	ER positive	Invasive Breast Carcinoma	Anastrozole
HPRA (1)	PR positive	Invasive Breast Carcinoma	Anastrozole
HPRA (1)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole

Contributions

Date	Contributor	Description
2024-11-10	Van Allen lab	Adding HRPA approvals for use to database